Want to see BAYRY full AI Analyst Report?
EBITDA by Segment
Reveals the profitability of each business unit before interest, taxes, depreciation, and amortization, indicating which segments drive earnings and operational efficiency.Bayer's Crop Science segment shows significant volatility, with recent quarters reflecting a downturn, possibly due to market pressures or strategic shifts. Pharmaceutical EBITDA has been relatively stable but shows a slight downward trend, indicating potential challenges in maintaining growth. Consumer Health remains consistent, suggesting resilience in this segment. Without recent earnings call insights, investors should monitor external factors affecting Crop Science and strategic moves in Pharmaceuticals to gauge future performance.
Date | Crop Science | Pharmaceutical | Consumer Health |
|---|---|---|---|
Mar 31, 2025 | €2.56B | €1.34B | €342.00M |
Dec 31, 2024 | €917.00M | €1.10B | €361.00M |
Sep 30, 2024 | €35.00M | €1.10B | €360.00M |
Jun 30, 2024 | €524.00M | €1.32B | €314.00M |
Mar 31, 2024 | €2.85B | €1.19B | €331.00M |
Dec 31, 2023 | €1.07B | €1.27B | €384.00M |
Sep 30, 2023 | -€24.00M | €1.44B | €313.00M |
Jun 30, 2023 | €725.00M | €1.38B | €335.00M |
Mar 31, 2023 | €3.27B | €1.11B | €379.00M |
Dec 31, 2022 | €820.00M | €1.43B | €313.00M |